Alert detail
LCD L39614: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — WPS
What changed
Covers molecular biomarker testing for skin cancer risk stratification.
Who’s affected: Oncology billing teams · Effective: May 28, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 2 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.